Hans van Eenennaam
Hans van Eenennaam, Ph.D., a chemist by training, has nearly 15 years of experience in the pharmaceutical and biotechnology industry and in-depth expertise in the field of immunology. He currently serves as chief operational officer and executive director of Aduro Biotech Europe, a subsidiary of Berkley, California-based Aduro Biotech, where he leads the development of new anti-cancer antibodies using the company’s proprietary B-select antibody technology. Prior to its acquisition by Aduro in 2015, Dr. van Eenennaam served as chief operational officer of BioNovion, a company he co-founded in 2011 to focus on the development of innovative therapeutic antibodies in the field of immune oncology. Earlier in his career, he held numerous positions of increasing responsibility at Organon in Oss, Netherlands, and then the Organon Research Center in Cambridge, Massachusetts (acquired by Schering-Plough Corporation in 2007 and later by Merck & Co.), where he led the discovery and development of therapeutic monoclonal antibodies and small molecule inhibitors. While at Merck, Dr. van Eenennaam, in cooperation with a team of scientists, discovered pembrolizumab (Keytruda®), a humanized therapeutic antibody approved in 2014 by the U.S. Food and Drug Administration for the treatment of melanoma and subsequently for additional indications including, non-small cell lung cancer and head and neck cancer. He is named as inventor on seven pending and granted patent families and author on over 25 publications. Dr. van Eenennaam received his doctorate in autoimmune biochemistry (cum laude) from Radboud University in Nijmegen, Netherlands.